Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Madison Air Q1 2026 Earnings Call - Backlog Surges 116% as IPO Deleveraging Drives Margin Expansion
Madison Air’s first quarter as a public company delivered a clean bill of health for its new management team. Pro forma net sales rose 13% to $924 million, driven by a 41% surge in commercial orders a...
- Record backlog of $2.5 billion, up 116% year-over-year, driven by a 1.4x book-to-bill ratio and strong commercial order momentum.
- Pro forma net sales grew 13% to $924 million, with commercial sales up 18% on a combined basis and residential flat on a combined basis but up 60% reported due to AprilAire.
- Adjusted EBITDA rose 16% to $233 million (implied from 25.3% margin), with margins expanding 70 basis points to 25.3% despite ongoing growth investments.
- +9 more takeaways
Scholar Rock Q1 2026 Earnings Call - FDA Accepts Apitegromab BLA for SMA with Dual Manufacturing Pathways
Scholar Rock has cleared a major regulatory hurdle with the FDA's acceptance of its Biologics License Application for apitegromab, the world's first muscle-targeted therapy for spinal muscular atrophy...
- FDA acceptance of the apitegromab BLA for SMA establishes a PDUFA date of September 30, 2026.
- Scholar Rock included two independent fill-finish facilities in its BLA, providing dual pathways to approval and de-risking the supply chain.
- The FDA completed an unannounced re-inspection of the Catalent, Indiana facility, with a 90-day classification window remaining.
- +8 more takeaways
Phibro Animal Health Corporation Q3 2026 Earnings Call - Sales Surge 10%, Upgraded Guidance, and Brazil Regulatory Transition
Phibro Animal Health delivered a solid third quarter in fiscal 2026, with net sales climbing 10% to $383.5 million and adjusted EBITDA rising 11% to $60 million. The growth was driven by a 13% jump in...
- Net sales increased 10% to $383.5 million, with Animal Health sales up 13% to $291.2 million.
- Adjusted EBITDA rose 11% to $60 million, driven by higher gross profit and strong demand across key segments.
- Full-year fiscal 2026 guidance was raised, with net sales now projected at $1.46B-$1.5B and adjusted EBITDA at $247M-$255M.
- +7 more takeaways
Collegium Pharmaceutical Q1 2026 Earnings Call - AZSTARYS Acquisition Accelerates ADHD Growth Trajectory
Collegium Pharmaceutical delivered a strong first quarter in 2026, driven by double-digit growth in its ADHD franchise and durable cash flows from its pain portfolio. Total net product revenues rose 9...
- JORNAY PM net revenue surged 36% year-over-year to $38.9 million, with prescriptions growing 14% and prescriber count hitting a record 30,000.
- Total net product revenues reached $193.5 million, up 9% year-over-year, with adjusted EBITDA rising 9% to $103.9 million.
- The pain portfolio generated $154.6 million in revenue, up 4%, driven by price increases and gross-to-net benefits that offset seasonal volume pressure.
- +7 more takeaways
Shift4 Payments Q1 2026 Earnings Call - International Expansion and AI-Driven Efficiency Drive Growth Amid Geopolitical Headwinds
Shift4 Payments delivered solid Q1 2026 results, with gross revenue less network fees (GRLNF) up 49% year-over-year to $549 million and adjusted EBITDA up 39% to $234 million. The company navigated a ...
- Gross revenue less network fees (GRLNF) grew 49% year-over-year to $549 million, in line with guidance.
- Adjusted EBITDA increased 39% year-over-year to $234 million, maintaining a 43% margin.
- Payments-based revenue less network fees surged 25% year-over-year, with worldwide growth reaching 51% and Americas growth at 15%.
- +7 more takeaways
Host Hotels & Resorts Q1 2026 Earnings Call - Raising 2026 Guidance on Resort Strength and Capital Discipline
Host Hotels & Resorts reported a strong first quarter, delivering adjusted EBITDAre of $543 million and raising its full-year comparable hotel RevPAR guidance to 3%-4.5%. The outperformance was driven...
- Host Hotels raised its 2026 comparable hotel RevPAR guidance to 3%-4.5% and total RevPAR to 3.5%-5%, citing resilient demand and strong out-of-room spending trends.
- First quarter adjusted EBITDAre reached $543 million, a 5.6% increase year-over-year, driven by rate growth and a 70 basis point expansion in comparable hotel EBITDA margins.
- Resort properties in Florida and Phoenix led transient revenue growth, which jumped 5.5% year-over-year, as affluent consumers shifted travel to U.S. destinations amid geopolitical uncertainty.
- +7 more takeaways
MKS Instruments Q1 2026 Earnings Call - AI-Driven Complexity Fuels Record Revenue and Aggressive Q2 Guidance
MKS Instruments delivered a blistering Q1 2026, crushing guidance with $1.08 billion in revenue and $2.30 in EPS. The semiconductor and electronics segments are riding a dual wave of AI infrastructure...
- Q1 2026 revenue hit $1.08 billion, up 15% year-over-year and 4% sequentially, surpassing the high end of guidance.
- Semiconductor revenue grew 13% year-over-year to $466 million, driven by broad-based strength in DRAM, NAND, and logic applications.
- Electronics and packaging revenue surged 27% year-over-year to $321 million, fueled by flexible PCB drilling and AI-related chemistry demand.
- +11 more takeaways
"Lantheus" Q1 2026 Earnings Call - PSMA Franchise Transition and Regulatory Milestones Drive 2027 Growth
Lantheus delivered a solid Q1 2026 start, with revenue of $377.3 million driven by PYLARIFY, Neuraceq, and DEFINITY. The company secured FDA approval for PYLARIFY TruVu and received tentative approval...
- Q1 2026 revenue reached $377.3 million, a 1.2% year-over-year increase, or 8.6% adjusted for divested SPECT revenues.
- PYLARIFY U.S. volume grew 5.8% year-over-year, with stable net ASP and sequential performance despite competitive pressures.
- Neuraceq revenue jumped 14.3% sequentially to $35.4 million, driven by Alzheimer’s DMT adoption and expanded PMF footprint.
- +7 more takeaways
Stevanato Group Q1 2026 Earnings Call - GLP-1 Demand Drives 10% Revenue Growth as Engineering Segment Faces Slow Order Intake
Stevanato Group kicked off fiscal 2026 with 10% constant-currency revenue growth, fueled by a 13% jump in its drug containment and delivery solutions (BDS) segment. High-value solutions, including pre...
- Revenue grew 10% on a constant currency basis to EUR 273.6 million, with the BDS segment up 13% and the engineering segment down 31%.
- GLP-1 therapies represented 21%-22% of total Q1 revenue, driving a 15% increase in biologics demand and reinforcing a long-term secular tailwind.
- High-value solutions accounted for 47% of total revenue, up 17% year-over-year, with prefillable syringes and EZ-fill vials leading the growth.
- +7 more takeaways
Amylyx Pharmaceuticals Q1 2026 Earnings Call - Avexitide LUCIDITY Trial Nearing Top-Line Readout with NDA Drafting Underway
Amylyx Pharmaceuticals advanced its pipeline in Q1 2026, with the phase III LUCIDITY trial for avexitide fully enrolled and poised for top-line data in Q3 2026. The company is simultaneously drafting ...
- Phase III LUCIDITY trial for avexitide fully enrolled, with top-line data expected in Q3 2026
- NDA drafting underway to accelerate regulatory submission timeline if trial results are positive
- Expanded access program launched for up to 250 U.S. patients with post-bariatric hypoglycemia (PBH)
- +7 more takeaways